A carregar...
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
The introduction of vedolizumab, a lymphocyte adhesion inhibitor, has expanded the relatively limited therapeutic armamentarium available for Crohn’s disease and ulcerative colitis. Despite its effectiveness, both primary nonresponse and secondary loss of response to vedolizumab do occur, as is obse...
Na minha lista:
| Publicado no: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5949937/ https://ncbi.nlm.nih.gov/pubmed/29774052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818772786 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|